Related Experiment Video

Updated: May 16, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Acromegalic cardiomyopathy with end-stage heart failure treated with left ventricular assist device: a case report

Liting Guo1, Hui Zheng2, Zhigang Liu3

  • 1Department of Endocrinology, TEDA International Cardiovascular Hospital, Tianjin Medical University, No. 61, Third Avenue, Teda, Tianjin, 300457, China.

Journal of Medical Case Reports
|May 14, 2026
PubMed

Insights

Left ventricular assist device (LVAD) implantation offers a promising treatment for heart failure caused by acromegaly. This case study shows complete symptom relief and stable cardiac condition after LVAD implantation in a patient with severe acromegaly-related heart failure.

Area of Science:

  • Cardiology
  • Endocrinology
  • Medical Case Studies

Background:

  • Acromegaly-related heart failure is a rare condition with challenging diagnosis and suboptimal treatment outcomes.
  • Standard treatments include managing heart failure symptoms and reducing growth hormone (GH) levels.
  • Left ventricular assist device (LVAD) presents a potential therapeutic avenue for these patients.

Purpose of the Study:

  • To present a case study of a patient with severe acromegaly-related heart failure.
  • To evaluate the efficacy of LVAD implantation in managing this condition.

Main Methods:

  • A 54-year-old female with New York Heart Association class IV heart failure was treated.
  • Acromegaly was diagnosed via clinical features, elevated GH, and pituitary macroadenoma.
  • Bromocriptine was administered for GH reduction, followed by LVAD implantation.

Main Results:

  • The patient experienced complete relief of cardiac symptoms within one week post-LVAD surgery.
  • Cardiac condition remained stable during one year of follow-up.
  • Growth hormone levels gradually decreased post-treatment.

Conclusions:

  • LVAD implantation can be an effective treatment for patients suffering from acromegaly-related heart failure.
  • This approach led to significant clinical improvement and stable outcomes in the presented case.
Abstract

Keywords:
Acromegalic cardiomyopathyAcromegalyCase reportEnd-stage heart failureLeft ventricular assist device

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...